The Korean biotech company published the multicenter Phase 1 results in Nature, with 24-week follow-up MRI data that look promising as they continue development.
A phase 2 trial found that adding a lab-expanded stem cell product made from multiple pooled cord blood donors to a single cord blood transplant may broaden access to transplants for leukemia...
Mesoblast said its 300-patient placebo-controlled Phase 3 study of rexlemestrocel-L for chronic low back pain remains on track, with top-line data expected in mid-2027 to support a planned FDA filing for the...
The San Diego non-profit has received a $12.7 million grant to advance scaffold-free tissue engineering research aimed at repairing knee cartilage and bone damage.
Researchers report that intranasal Muse cells improved motor function and reduced neurodegeneration in a Parkinson’s mouse model.
The trial found no significant difference in pain or function outcomes between bone marrow injections and sham procedures over 12 months, but also had important limitations.
Researchers are testing a minimally invasive stem cell patch that could reduce the need for transplants.
What appeared to be a potential stem cell breakthrough is slowly being torn apart by peer-reviewers, who found damning inconsistencies in the data.
Researchers are examining how platelet-rich plasma may help adipose-derived stem cells move more effectively to support muscle repair.
Is the cart before the horse on orthopedic stem cell therapy?
